US OptionsDetailed Quotes
SIGA250117P6450
- 0.25
- -0.04-13.79%
15min DelayClose Jan 17 16:00 ET
0.28High0.20Low
0.24Open0.29Pre Close401 Volume1.77K Open Interest6.45Strike Price9.33KTurnover4038.64%IV0.40%PremiumJan 17, 2025Expiry Date0.23Intrinsic Value100Multiplier-2DDays to Expiry0.03Extrinsic Value100Contract SizeAmericanOptions Type-0.8110Delta1.1029Gamma24.90Leverage Ratio-95.8907Theta0.0000Rho-20.19Eff Leverage0.0000Vega
SIGA Technologies Stock Discussion
1. NFA (Not Financial Advice!)
2. Do not open position without chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 CH (cash on hand); AH (after hours): RTH (regular trading hours); PM (pre market)
7. Remember, some stocks may get pumped WITHOUT any catalyst
8. It’s 2025, those newbies need to read and ed...
Tepoxx (Tecovirimat) Approved in Japan for the Treatment of Orthopoxviruses
Wow almost bought in too...
SIGA Technologies (SIGA) Shares Tumble After Mpox Therapy Fails, Chief Medical Officer Terminated - Hagens Berman
phew
SIGA Enters into Exclusive License Agreement with Vanderbilt University for Novel Poxvirus Monoclonal Antibodies
SIGA Technologies (NASDAQ: SIGA) has entered into an exclusive license agreement with Vanderbilt University for a portfolio of preclinical fully human monoclonal antibodies (mAbs). These mAbs have potential as treatments for a broad range of orthopoxviruses, including smallpox and mpox. The agreement grants SIGA exclusive rights to develop, manufacture...
SIGA Technologies Inc - Contract in Response to Morocco Ministry of Health Request. Makes first commercial sale in Africa
SIGA Announces Agreement to Supply TPOXX® in Morocco
No comment yet